Use of IL3 and chromatin-modifying reagents valproic acid and 5-aza-2′-deoxycytidine to affect mobilized peripheral blood CD34+ cell fate decisions

Vox Sanguinis

Volumn 107, Issue 1, 2014, Pages 83-89

  Liu, J ^a   Samuel, K ^a   Turner, M L ^a   Gallagher, R C J ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

5 aza 2 deoxycytidine; Differentiation; Erythrocyte; Valproic acid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; INTERLEUKIN 3; VALPROIC ACID; AZACITIDINE; CD34 ANTIGEN; CHROMATIN;

ARTICLE; BLOOD; CELL CULTURE; CELL FATE; CELL GROWTH; CFU COUNTING; CHROMATIN; COLONY FORMING CELL; CONTROLLED STUDY; ERYTHROID CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMOBILIZED CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL; AGED; ANALOGS AND DERIVATIVES; BLOOD CELL; CELL DIFFERENTIATION; DRUG EFFECTS; HEMATOPOIETIC STEM CELL; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; ANTIGENS, CD34; AZACITIDINE; BLOOD CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; CHROMATIN; COLONY-FORMING UNITS ASSAY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-3; MALE; MIDDLE AGED; VALPROIC ACID;

EID: 84902313927     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12124     Document Type: Article

References (16)

1. Chaurasia P, Berenzon D, Hoffman R: Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. Blood 2011; 117:4632-4641
2. Suzuki M, Harashima A, Okochi A et al.: 5-Azacytidine supports the long-term repopulating activity of cord blood CD34(+) cells. Am J Hematol 2004; 77:313-315
3. Walasek MA, Bystrykh L, van den Boom V et al.: The combination of valproic acid and lithium delays hematopoietic stem/progenitor cell differentiation. Blood 2012; 119:3050-3059
4. + cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO. J Transl Med 2007; 5:53
5. Chiu CT, Wang Z, Hunsberger JG et al.: Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 2013; 65:105-142
6. Leone G, Teofili L, Voso MT et al.: DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87:1324-1341
7. Chateauvieux S, Eifes S, Morceau F et al.: Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochem Pharmacol 2011; 81:498-509
8. Liu B, Ohishi K, Yamamura K et al.: A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis. Exp Hematol 2010; 38:685-695
9. Andrews RG, Singer JW, Bernstein ID: Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986; 67:842-845
10. Civin CI, Strauss LC, Brovall C et al.: Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133:157-165
11. Huang E, Nocka K, Beier DR et al.: The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990; 63:225-233
12. Katz FE, Tindle R, Sutherland DR et al.: Identification of a membrane glycoprotein associated with haemopoietic progenitor cells. Leuk Res 1985; 9:191-198
13. Chen L, Gao Z, Zhu J et al.: Identification of CD13+ CD36+ cells as a common progenitor for erythroid and myeloid lineages in human bone marrow. Exp Hematol 2007; 35:1047-1055
14. British National Formulary: London, UK, Pharmaceutical Press, 2013
15. Kieslich M, Schwabe D, Cinatl J Jr et al.: Increase of fetal hemoglobin synthesis indicating differentiation induction in children receiving valproic acid. Pediatr Hematol Oncol 2003; 20:15-22
16. Woo AJ, Kim J, Xu J et al.: Role of ZBP-89 in human globin gene regulation and erythroid differentiation. Blood 2011; 118:3684-3693